Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...

Drug executives talked M&A and the incoming administration, but also weighed the outlook for cell and gene therapy developers ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his ...

Agency commissioners voted unanimously on Tuesday to publish the report, which makes a similar attack on the drug middlemen ...

The review, which was spurred by controversy over the FDA's Aduhelm approval, recommends two main changes in agency ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

The pharma began submitting its TAR-200 bladder cancer treatment to the FDA. Elsewhere, Sarepta and Madrigal reported strong ...

NULISA employs a sequential immunocomplex capture and release technique to improve the sensitivity of traditional proximity ...

Executives at Amgen made the case for MariTide's differentiation, while Merck's CEO contended Keytruda's coming loss of exclusivity can be managed.